Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Clinical trial NCT06731478 · RECRUITING
Trial details
- NCT number
- NCT06731478
- Sponsor
- Daiichi Sankyo
- Status
- RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2025-02-27
- Primary completion
- 2028-06-01
- Enrollment
- 726
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.